Immune Responses to Tozinameran S Antigen

Tozinameran's spike antigen induces robust neutralizing antibody responses peaking at 2-4 weeks that decline over 6 months, alongside persistent spike-specific Th1-type CD4+ and cytotoxic CD8+ T cell responses with long-lived memory populations showing superior variant cross-reactivity.

Abstract

BNT162b2 (Tozinameran) vaccination induces robust spike-specific humoral and cellular immune responses in immunocompetent populations, with 95-98% seroconversion after two doses and peak neutralizing antibody levels at 2-4 weeks post-second dose. Antibody titers decline substantially over 6 months, with 50-90% reductions from peak levels, though this occurs alongside persistent spike-specific memory T and B cells capable of recall responses through 9 months. Cellular immunity emerges early, with T cell responses detectable by day 15, characterized by Th1-type CD4+ cells expressing IL-2, IFN-γ, and TNF-α and cytotoxic CD8+ responses. T stem cell memory populations persist stably through 6 months in 88% of individuals. Prior SARS-CoV-2 infection profoundly amplifies vaccine responses, with recovered individuals achieving peak neutralizing antibody titers after a single dose equivalent to two-dose vaccination in naïve individuals. However, immunocompromised populations show markedly attenuated responses, with dialysis patients achieving only 88.9% seroconversion and 67.7% T cell response rates compared to 93.3% in age-matched controls.

Cellular immunity demonstrates superior cross-reactivity with variants compared to humoral responses. While Beta (B.1.351) variant neutralization shows 2- to 10-fold reductions, CD4+ T cell activation remains unaffected by mutations in B.1.1.7 and B.1.351 variants, with no significant differences in T cell responses against Beta and Delta variants. Age negatively correlates with antibody magnitude and persistence, while T cell responses decline in individuals with increased immunosenescent CD8+ TEMRA cells. Booster doses administered 6-12 months post-vaccination restore waning antibody responses, with greater benefit observed in naïve versus previously infected individuals. The evidence indicates Tozinameran’s spike antigen elicits complementary humoral and cellular immunity, with antibodies providing initial sterilizing protection that wanes over months while durable memory T cell populations persist to enable rapid recall responses upon antigen re-exposure.

Results

Characteristics of Included Studies

All 10 studies evaluated immune responses following BNT162b2 (Tozinameran) vaccination, with full texts available for 7 studies and abstract-only data for 3 studies. Study designs, populations, and follow-up durations varied substantially across the included evidence.

Neutralizing Antibody Responses

Seroconversion Rates and Antibody Titers

Studies consistently demonstrated high seroconversion rates following two-dose vaccination in immunocompetent populations, though with notable variation in timing and magnitude. Among dialysis patients, only 55.6% developed SARS-CoV-2 IgG antibodies at the first sampling (~1 week post-second dose), increasing to 88.9% at 3-4 weeks and declining to 84.4% at 10 weeks. In contrast, 98.4% of immunocompetent naïve healthcare workers developed both neutralizing antibodies and specific T cells after the second dose.

Antibody kinetics showed consistent patterns across studies. Guerrera et al. reported median neutralizing antibody levels of 28 at the day of boost (T1), peaking at 1786 fourteen days later (T2), and declining to 517 at 6 months (T3). Takeuchi et al. found no participants were seropositive on day 15, rising to 96% on day 29, then decreasing to 81% and 58% on days 61 and 82-96 respectively. The magnitude of decline was substantial: IgG-S-RBD titers decreased by 53.1% at day 61, 73.7% at day 82-96, and 96.2% at day 263 compared to peak levels on day 29.

The observed decline in antibody levels was consistent with waning immunity over time. Naaber et al. found that antibody levels at 6 months post-vaccination were similar to those in individuals who received only one dose or recovered from COVID-19, indicating substantial reduction from peak levels.

Neutralization Capacity Against Variants

Studies evaluating variant cross-reactivity revealed differential neutralization capacity depending on the specific variant tested. For the B.1.1.7 (Alpha) variant, Geers et al. reported higher neutralizing antibody titers compared to wild-type virus (2.5-fold and 2.2-fold increases). However, the B.1.351 (Beta) variant showed consistent immune escape, with 2.7-fold and 3.3-fold decreases in neutralizing capacity and approximately 10-fold reduction in neutralizing antibody levels compared to the parent strain. Among immunocompetent naïve subjects, 80.9% retained detectable neutralizing antibodies against the Beta variant and 86.2% against the Delta variant.

Temporal decline in variant neutralization was evident. Naaber et al. found that antibodies efficiently blocked ACE2 receptor binding to spike proteins of five variants of concern at one week post-vaccination, but this capacity decreased by three months. The fold-reduction in neutralization against B.1.351 compared to the original strain was consistently 2- to 4-fold across antibody-based assays.

Effects of Prior SARS-CoV-2 Infection

Prior SARS-CoV-2 infection substantially amplified humoral responses. Geers et al. demonstrated that recovered individuals achieved a geometric mean plateau PRNT50 titer of 1:1874 after a single vaccination, with no further increase after the second dose. In contrast, naïve individuals required two doses to achieve comparable levels, with only 7 of 12 developing neutralizing antibodies after one dose, rising to 12 of 12 after the second. Desmecht et al. confirmed higher anti-spike antibody levels and neutralization capacity in experienced versus naïve individuals at all timepoints prior to booster administration. Median neutralization titers in experienced individuals reached 1:640 after the first dose, while naïve individuals showed minimal increase.

Cellular Immune Responses

CD4+ and CD8+ T Cell Activation

T cell responses were detected across multiple studies using various assay methods. Among dialysis patients, 67.7% demonstrated SARS-CoV-2-specific T cell responses 3 weeks after the second vaccination, significantly lower than 93.3% in age-matched controls. Takeuchi et al. found that T cell responses, measured by IFN-γ production using the QuantiFERON SARS-CoV-2 assay, were detected as early as day 15 after the first dose and peaked after the second dose before declining over time. Positive T cell responses were defined as ≥0.20 IU/mL IFN-γ concentration.

Desmecht et al. found experienced individuals had higher cellular immunity compared to naïve individuals at 6 months (T4), though this difference disappeared after the booster dose. The correlation between anti-spike IgG and IFN-γ was more pronounced in experienced individuals.

Memory T Cell Formation and Phenotypes

Guerrera et al. provided detailed characterization of memory T cell phenotypes, demonstrating that BNT162b2 induced CD4+ T stem cell memory (TSCM) detectable in 88% of individuals, with levels increasing from baseline to 6 months. These cells displayed markers of immunological maturity and stem cell memory, surviving the physiological contraction phase and persisting for at least 6 months. El-Orfali et al. confirmed that vaccination resulted in spike-specific memory CD4+ T cells that proliferate upon reactivation, promote a protective Th1 response, and induce IgG/IgA class switching in memory B cells. Memory CD8+ T cells similarly proliferated upon reactivation and upregulated granzyme and perforin to eliminate infected cells.

The temporal emergence of T cell responses was notable. Takeuchi et al. observed that T cell responses were detected on day 15, earlier than the onset of neutralizing antibody activity, suggesting T cells may provide initial protection before robust humoral immunity develops. This early T cell activation preceded peak antibody responses by approximately 2 weeks.

T Cell Cross-Reactivity with Variants

In contrast to the partial escape observed with humoral immunity, cellular immunity demonstrated robust cross-reactivity across variants. Geers et al. found no differences in CD4+ T cell activation when peripheral blood mononuclear cells were stimulated with peptide pools spanning the mutated spike regions of B.1.1.7 and B.1.351, indicating that these variants do not escape T cell-mediated immunity. CD4+ T cells equally recognized wild-type, B.1.1.7, and B.1.351 spike proteins. Cassaniti et al. similarly reported that T cell responses were less affected by SARS-CoV-2 variants, with no significant difference in the frequency of responders when challenged with Beta and Delta variants.

Response Kinetics and Durability

Temporal Dynamics of Immune Responses

The kinetics of antibody and T cell responses followed distinct but complementary trajectories. Guerrera et al. documented that antibody responses appeared before high titers developed, displaying markers of immunological maturity, and survived physiological contraction for at least 6 months. Peak antibody responses occurred 14 days after the second dose (T2), with median levels of 1786, declining to 517 at 6 months. T stem cell memory cells remained stable throughout this period.

Pulendran and Arunachalam measured responses at baseline, day 21, and day 42 post-vaccination, finding peak antibody responses around day 42 with approximately 5-fold increases after the second dose compared to the first. Cellular immunity was more readily detectable 7 days after the second dose. Innate immune responses showed different kinetics, with cytokine levels returning to baseline by day 28.

Long-Term Persistence and Waning Immunity

Long-term follow-up revealed progressive decline in humoral immunity with more stable cellular responses. Takeuchi et al. found immune responses sustained for approximately 6 to 10 weeks but not beyond 7 months following the second vaccination. The decline in IgG-S-RBD titers was substantial: 53.1% at day 61, 73.7% at day 82-96, and 96.2% at day 263 compared to peak levels. Similarly, anti-SARS-CoV-2 IgA decreased from 91.67% at 3-4 weeks to 59.38% at 10 weeks in dialysis patients.

Desmecht et al. provided the longest follow-up data, showing immune responses detectable up to 12 months. However, antibody levels declined substantially, particularly in naïve individuals, necessitating booster doses. El-Orfali et al. demonstrated that spike-specific memory T and B cells persisted for up to 9 months post-immunization and could mount recall responses upon antigen reactivation.

The comparison between first and second dose responses revealed amplification effects. Desmecht et al. found higher antibody titers in the experienced group after the first dose, with peak responses occurring two weeks after the second dose in naïve individuals. Payne et al. showed that extended dosing intervals (6-14 weeks vs 3-4 weeks) resulted in higher neutralizing antibody levels and enrichment of IL-2-expressing CD4+ T cells.

Response Modifying Factors

Age and Immunosenescence

Age emerged as a consistent negative predictor of antibody responses across multiple studies. Naaber et al. found antibody responses correlated negatively with age, while Guerrera et al. reported that vaccine effectiveness decreases with age and antibody titers correlate negatively with age. However, the relationship was more nuanced for cellular immunity. Naaber et al. observed that T cell responses were lower in individuals with increased proportions of immunosenescent CD8+ TEMRA cells, a marker of immune aging. Pulendran and Arunachalam documented age-related differences in response patterns: younger subjects had greater changes in monocyte and inflammatory responses, while older subjects showed increased responses in B and T cell modules. Despite these differences, no significant difference in neutralizing antibody responses existed between males and females.

Takeuchi et al. found younger age (<40 years) was associated with higher IgG-S-RBD titers, while Desmecht et al. confirmed a significant negative association between age and persistence of humoral responses. The age effect on antibody responses appeared stronger than the effect on cellular immunity, though both were influenced by advancing age.

Impact of Prior SARS-CoV-2 Infection

Prior infection was the strongest amplifier of vaccine-induced immunity across all studies that examined this factor. Geers et al. found recovered individuals showed a recall response with high levels of antibodies and T cells after a single vaccination, sufficient to match or exceed naïve individuals receiving two doses. Payne et al. confirmed that prior infection amplified and accelerated the immune response, while Cassaniti et al. reported increased immunogenicity in experienced subjects, with sustained neutralizing antibody activity against all tested variants.

Desmecht et al. provided the most comprehensive analysis, showing experienced individuals had higher anti-spike antibodies and neutralization capacity at all timepoints prior to booster administration. The median neutralization titer in experienced individuals increased to 1:640 after the first dose, while naïve individuals showed minimal increase.

Comorbidities and Immunocompromised States

Schrezenmeier et al.’s study of dialysis patients revealed profound effects of chronic kidney disease on vaccine immunogenicity. Only 55.6% of dialysis patients developed SARS-CoV-2 IgG antibodies at the first sampling, increasing to 88.9% at the second sampling, compared to near-universal seroconversion in immunocompetent populations. T cell responses were similarly impaired, with 67.7% of dialysis patients showing responses compared to 93.3% in age-matched controls. Multiple mechanisms likely contributed to this impairment, including decreased B and T cell counts, impaired clearance of uremic toxins, systemic inflammation, and malnutrition.

The magnitude of antibody responses was also reduced. Schrezenmeier et al. found significantly lower seroconversion rates and antibody titers in dialysis patients compared to age-matched non-dialysis controls. Gender differences were noted but appeared attenuated by advanced age. These findings highlighted the vulnerability of immunocompromised populations and suggested the need for modified vaccination strategies, including additional booster doses.

Sex and Body Mass Index

Sex differences in immune responses showed variable patterns across studies. Guerrera et al. reported comparable antibody levels between males and females, though females retained lower levels of neutralizing antibodies at 6 months. Takeuchi et al. found females tended to have higher IgG-S-RBD titers, though this was a trend rather than a statistically significant difference. Conversely, males showed higher IFN-γ production by CD4+ T cells on day 29, suggesting potential sex-specific differences in cellular versus humoral immunity balance.

Body mass index also influenced responses, with Takeuchi et al. reporting that individuals with normal BMI tended to have higher IgG-S-RBD titers compared to those with higher BMI. However, no significant differences in T cell responses were observed based on BMI.

Booster Dose Effects

Two studies specifically examined the impact of booster doses administered 6-12 months after initial vaccination. Desmecht et al. found the booster dose induced substantial increases in both humoral and cellular immune responses, particularly in naïve individuals. Neutralization capacity, which had decreased in naïve individuals by 6 months (T4), was restored after the booster. The benefit of the booster dose was greater in naïve individuals compared to those with prior infection, suggesting that hybrid immunity (vaccination plus natural infection) provided more durable protection than vaccination alone.

El-Orfali et al. confirmed that blood samples taken at 1, 3, 6, and 9 months post-booster dose showed sustained spike-specific memory T and B cell responses capable of mounting recall responses upon reactivation. Memory B cells were primed to secrete neutralizing antibodies upon reactivation, while memory CD4+ T cells promoted protective Th1 responses and induced IgG/IgA class switching.

Synthesis

The included studies revealed substantial heterogeneity in immune response magnitude and durability, driven by distinct population characteristics, prior infection status, age, and comorbid conditions rather than conflicting findings. Three key patterns emerged that reconcile apparent discrepancies.

First, population-specific immune capacity determined baseline vaccine responsiveness. Studies of healthy adults and healthcare workers consistently reported >95% seroconversion after two doses, while dialysis patients achieved only 88.9% seroconversion with significantly lower antibody titers and T cell responses (67.7% vs 93.3% in controls). This divergence reflects fundamental differences in immune competence rather than vaccine failure. Dialysis patients exhibit decreased B and T cell counts, impaired toxin clearance, systemic inflammation, and malnutrition—mechanistic factors that predict attenuated responses to any vaccine. The appropriate conclusion is not that BNT162b2 has variable efficacy, but that immunocompromised populations require augmented vaccination strategies (additional doses, higher antigen loads, or adjuvants) to achieve protection comparable to healthy cohorts.

Second, prior SARS-CoV-2 infection created a distinct immunological state that fundamentally altered vaccine kinetics and magnitude. Hybrid immunity (infection plus vaccination) consistently produced higher and more durable responses than vaccination alone. Geers et al. showed that recovered individuals achieved peak neutralizing antibody titers (geometric mean 1:1874) after a single vaccine dose with no further increase after the second, while naïve individuals required two doses to reach comparable levels. Desmecht et al. extended this finding across the full vaccination course, demonstrating experienced individuals maintained higher anti-spike antibodies and neutralization capacity at all timepoints. The mechanistic explanation involves memory B cell priming: prior infection establishes antigen-specific memory cells that undergo rapid proliferation and affinity maturation upon vaccine boost, bypassing the slower germinal center reaction required in naïve individuals. This explains why booster doses provided greater benefit to naïve individuals—they were reaching parity with the immune state already achieved through hybrid immunity. Critically, cellular immunity showed even more pronounced advantages in experienced individuals, with stronger T cell responses at 6 months and robust cross-reactivity maintained against variants.

Third, the temporal decline in antibody levels does not indicate vaccine failure but rather normal immune contraction following resolution of acute antigenic stimulation. Multiple studies documented 50-90% reductions in antibody titers between peak (2-4 weeks post-second dose) and 6 months. However, this occurred alongside stable or increasing memory T cell populations, particularly CD4+ T stem cell memory (TSCM) cells that persisted through 6 months. The mechanistic framework explains this pattern: following antigen clearance, short-lived plasma cells die off while long-lived plasma cells migrate to bone marrow niches and memory B cells enter quiescence. The observed antibody decline reflects contraction of the short-lived plasma cell pool, not loss of immunological memory. Supporting this, El-Orfali et al. demonstrated that memory B cells remained primed to secrete neutralizing antibodies upon reactivation through 9 months, while memory T cells proliferated and upregulated effector functions upon antigen re-exposure. The key metric is therefore not circulating antibody titer at arbitrary timepoints but rather memory cell persistence and recall capacity—both of which remained robust through available follow-up periods.

The apparent contradiction between waning antibody titers and claims of sustained immunity is reconciled by distinguishing between correlates of protection at different stages post-vaccination. In the first 3-6 months, high circulating antibody levels provide sterilizing immunity preventing infection. Beyond 6 months, as antibody levels decline, protection shifts toward memory-mediated responses that prevent severe disease. Takeuchi et al.’s finding that T cell responses appeared earlier than neutralizing antibodies (day 15 vs day 29) supports a model where cellular immunity provides a critical protective layer even before peak humoral responses develop and persists after antibody waning. This explains how breakthrough infections can occur in vaccinated individuals while severe disease remains rare—memory cells rapidly expand upon infection, containing viral replication before clinical deterioration.

Age effects operated through both quantitative and qualitative mechanisms. Older individuals showed reduced antibody titers and increased immunosenescence markers (CD8+ TEMRA cells), but Pulendran and Arunachalam revealed distinct age-stratified response patterns: younger subjects mounted stronger innate inflammatory responses while older subjects showed preserved or enhanced B and T cell module responses. This suggests age-related immune decline is not uniform across all compartments. The modest inverse correlation between age and neutralizing antibodies may be partially offset by compensatory increases in other protective mechanisms, explaining why real-world vaccine effectiveness against severe disease remained high across age groups despite lower antibody titers in elderly populations.

For variant cross-reactivity, the divergence between humoral and cellular immunity proved critical. Beta (B.1.351) variant showed 2- to 10-fold reductions in neutralizing antibody responses, raising concerns about immune escape. However, CD4+ T cell responses showed no impairment against Beta or Delta variants, with T cells equally recognizing wild-type and variant spike proteins. The mechanistic basis is epitope breadth: neutralizing antibodies target a limited set of RBD epitopes susceptible to single amino acid substitutions (K417N/T, E484K in Beta), while T cells recognize diverse linear epitopes across the entire spike protein, most of which are conserved across variants. This differential susceptibility explains why breakthrough infections increased with Beta despite maintained protection against severe disease—antibodies failed to prevent infection, but T cells controlled viral replication and pathology.

The studies collectively support a model where BNT162b2 induces robust humoral and cellular immunity in immunocompetent individuals, with response magnitude and durability strongly influenced by prior infection status, age, and immune competence. For healthy adults, two doses produce peak responses at 2-4 weeks with physiological contraction to steady-state memory by 6 months. For individuals with prior infection, a single dose achieves hybrid immunity superior to two-dose naïve vaccination. For immunocompromised populations, standard dosing produces suboptimal responses requiring augmented strategies. In all cases, cellular immunity proves more durable and cross-reactive than humoral immunity, suggesting memory T cells are the primary mediator of long-term protection against severe disease even as antibody-mediated protection against infection wanes.

References

D. Geers, M. Shamier, S. Bogers, G. den Hartog, L. Gommers, and 20 more (2021). SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients. Science immunology

G. Guerrera, M. Picozza, S. D’Orso, R. Placido, Marta Pirronello, and 11 more (2021). BNT162b2 vaccination induces durable SARS-CoV-2–specific T cells with a stem cell memory phenotype. Science immunology

P. Naaber, L. Tserel, K. Kangro, E. Sepp, Virge Jürjenson, and 10 more (2021). Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. The Lancet Regional Health - Europe

R. Payne, S. Longet, J. Austin, D. Skelly, W. Dejnirattisai, and 131 more (2021). Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell

B. Pulendran, P. Arunachalam (2021). Systems biological assessment of human immunity to BNT162b2 mRNA vaccination. Research Square

J. Takeuchi, A. Fukunaga, S. Yamamoto, A. Tanaka, K. Matsuda, and 10 more (2021). SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2: a 9 months longitudinal study. Scientific Reports

Salomé Desmecht, Aleksandr Tashkeev, Nicole Maréchal, Hélène Perée, Y. Tokunaga, and 16 more (2022). Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections. Frontiers in Immunology

Youmna El-Orfali, Rana H. Mansour, Habib Al-Kalamouni, Ziad C. Jabbour, Antoine G. Abou Fayad, and 3 more (2025). Longitudinal T and B cell recall responses following vaccination with the Pfizer-BioNTech mRNA vaccine BNT162b2. Journal of Allergy and Clinical Immunology

I. Cassaniti, F. Bergami, E. Percivalle, E. Gabanti, J. Sammartino, and 15 more (2021). Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study. Clinical Microbiology and Infection

E. Schrezenmeier, L. Bergfeld, D. Hillus, J. Lippert, Ulrike A. Weber, and 14 more (2021). Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis. Frontiers in Immunology